The role of EZH2 in overall survival of colorectal cancer: a meta-analysis
Open Access
- 23 October 2017
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 7 (1) , 1-8
Abstract
Enhancer of zeste homolog 2 (EZH2) is the catalitic subunit of polycomb repressive complex 2 and mediates gene silencing. EZH2 is overexpressed in many cancers and correlates with poor prognosis. The role of the gene EZH2 in colorectal cancer survival is uncertainly, the aim of this study is clear this relationship. Relevant literaure was searched from electronic databases. A meta-analysis was performed with elegible studies which quantitatively evaluated the relationship between EZH2 overexpression and survival of patients with colorectal cancer. Survival data were aggregated and quantitatively analyzed. We performed a meta-analysis of 8 studies (n = 1059 patients) that evaluated the correlation between EZH2 overexpression and survival in patients with colorectal cancer. Combined hazard ratios suggested that EZH2 overexpression was associated with better prognosis of overall survival (OS) HR(hazard ratio) = 0.61 95% CI (0.38–0.84) We performed bias analysis according Egger and Begg,s test and we did not find publication bias. EZH2 overexpression indicates a better prognosis for colorectal cancer.Keywords
This publication has 67 references indexed in Scilit:
- PRC2 overexpression and PRC2-target gene repression relating to poorer prognosis in small cell lung cancerScientific Reports, 2013
- Update of research on the role of EZH2 in cancer progressionOncoTargets and Therapy, 2013
- EZH2 Oncogenic Activity in Castration-Resistant Prostate Cancer Cells Is Polycomb-IndependentScience, 2012
- Increased EZH2 protein expression is associated with invasive urothelial carcinoma of the bladderUrologic Oncology: Seminars and Original Investigations, 2012
- The role of EZH2 and DNA methylation in the silencing of the tumour suppressor RUNX3 in colorectal cancerCarcinogenesis, 2010
- Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosisBritish Journal of Cancer, 2009
- Ezh1 and Ezh2 Maintain Repressive Chromatin through Different MechanismsMolecular Cell, 2008
- Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancersMolecular Carcinogenesis, 2008
- REporting recommendations for tumour MARKer prognostic studies (REMARK)British Journal of Cancer, 2005
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986